Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Technology evaluation: LErafAON, NeoPharm.

João Nuno Moreira1, Sérgio Simões

  • 1Laboratory of Pharmaceutical Technology, Faculty of Pharmacy and Center for Neurosciences and Cell Biology, University of Coimbra, Rua do Norte, Coimbra 3000-295, Portugal. jmoreira@ci.uc.pt

Current Opinion in Molecular Therapeutics
|November 7, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Antitumor Activity of Liposomal Nanoparticles Co-Encapsulating Ceramides and Doxorubicin in In Vitro Nucleolin-Expressing Neuroblastoma Models.

Cells·2026
Same author

Exploring the Potential Role of Manganese-Based Zeolitic Imidazolate Framework Nanoparticles in Cancer Therapy: <i>In vitro</i> Studies Using Lung Cancer Cells.

International journal of nanomedicine·2026
Same author

Characterization of Liquid Formulations for Enhanced Buccal Permeation: Exploring Key Attributes.

Biomedicines·2026
Same author

Patient-derived neuroblastoma models are sensitive to nucleolin-recognizing liposomal drugs.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2025
Same author

Corrigendum to "Unveiling the impact of membrane fluidity in shaping lipid-based drug delivery systems development." [Biochim. Biophys. Acta (BBA) - Biomembr. Volume 1868, Issue 1, January 2026, 184461].

Biochimica et biophysica acta. Biomembranes·2025
Same author

Unveiling the impact of membrane fluidity in shaping lipid-based drug delivery systems development.

Biochimica et biophysica acta. Biomembranes·2025
Same journal

Gene therapy: Have the risks associated with viral vectors been solved?

Current opinion in molecular therapeutics·2011
Same journal

Teduglutide, a glucagon-like peptide-2 analog for the treatment of gastrointestinal diseases, including short bowel syndrome.

Current opinion in molecular therapeutics·2010
Same journal

Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes.

Current opinion in molecular therapeutics·2010
Same journal

Corticorelin, a synthetic human corticotropin-releasing factor analog, for the treatment of peritumoral brain edema.

Current opinion in molecular therapeutics·2010
Same journal

Mogamulizumab, a humanized mAb against C-C chemokine receptor 4 for the potential treatment of T-cell lymphomas and asthma.

Current opinion in molecular therapeutics·2010
Same journal

Gevokizumab, an anti-IL-1β mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease.

Current opinion in molecular therapeutics·2010
See all related articles

NeoPharm is investigating liposome-encapsulated, c-Raf antisense oligodeoxynucleotides (LErafAON) as a potential cancer therapy. Early trials are exploring its efficacy against solid tumors resistant to standard treatments.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Development

Background:

  • Solid tumors, including those resistant to chemotherapy and radiation, represent a significant unmet medical need.
  • Targeting specific molecular pathways, such as the c-Raf kinase, offers a potential strategy for novel cancer therapies.
  • Antisense oligodeoxynucleotides (AONs) provide a mechanism to inhibit gene expression at the post-transcriptional level.

Purpose of the Study:

  • To evaluate the safety and preliminary efficacy of liposome-encapsulated, c-Raf antisense oligodeoxynucleotides (LErafAON) in patients with various solid tumors.
  • To assess the potential of LErafAON in treating tumors refractory to conventional therapies.

Main Methods:

  • Phase I/II clinical trials were initiated to assess the safety and tolerability of LErafAON.

Related Experiment Videos

  • The study involved patients with diverse solid tumor types, including those with resistance to radiation or chemotherapy.
  • Ongoing clinical evaluation was conducted from March 2001 to June 2003.

    • Main Results:

    • The abstract does not contain specific results, only that the trials were ongoing as of June 2003.
    • Further data collection and analysis were pending.

    Conclusions:

    • The development of LErafAON represents a novel therapeutic approach for solid tumors.
    • Clinical trials are essential to determine the ultimate benefit of this targeted therapy in cancer treatment.